---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OPERA-01"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OPERA-01. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 43 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence/opera-01"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OPERA-01

<a id="heading-3.1.1"></a>

## 3.1.1 OPERA-01

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Trial objective

> “OPERA-01 (NCT06016738) is a phase III study designed to evaluate the safety and efficacy of palazestrant monotherapy compared to SOC ET in patients with ER+, HER2– locally advanced or metastatic breast cancer, regardless of ESR1 mutation status, whose disease advanced following treatment with at least one ET in combination with a CDK4/6i.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.1-2"></a>

#### Registered objective and comparators

> “This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.1-3"></a>

#### Main objectives in the EU trial authorization

> “1. To evaluate the safety of OP-1250 at the dose levels of 90 and 120 mg”
> “2. To compare PFS, based on a BIRC assessment, between arms of OP-1250 at the selected dose and SOC treatment”

Source: [EU CTIS 2023-505871-63-00](https://euclinicaltrials.eu/ctis-public/view/2023-505871-63-00)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Registry dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2023-11-16” |
| Primary completion (estimated) | “2026-10-31” |
| Study completion (estimated) | “2028-02-29” |

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.2-2"></a>

#### Registration and start of enrollment

> “Clinical Trial Registration: Clinicaltrials.gov NCT06016738. Registered 17 August 2023.”
> “Enrollment began in November 2023.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.2-3"></a>

#### Countries with trial sites

> “Argentina Australia Austria Belgium Brazil Bulgaria Canada Czechia France Germany Hong Kong Hungary Italy Malaysia Mexico The Netherlands Poland Portugal Romania South Korea Spain Taiwan Thailand UK USA”

Source: [Pistilli et al. (2025)](https://ir.olema.com/static-files/61ec4071-51a5-4a03-aadb-1d296ccd53cb)

<a id="topic-3.1.1.2-4"></a>

#### Enrollment completion and expected top-line results

> “In November 2023, we initiated OPERA-01, our pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- MBC. We have completed enrollment and anticipate top-line results for this trial in the first quarter of 2027”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Randomized, open-label, two-part design

> “The OPERA-01 study is a global phase III randomized, open-label, active-controlled study, consisting of two parts (Figure 2).”
> “In Part 2, participants are randomized at a 1:1 ratio to receive once‑daily oral palazestrant (90 mg QD) or the investigator’s choice of SOC ET.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.3-2"></a>

#### Part 1 dose selection

> “In Part 1, the dose-selection portion of the study, eligible participants were randomized 1:1:1 to receive oral palazestrant at a dose of 90 mg or 120 mg once daily (QD) or investigator’s choice of SOC ET”
> “The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated in Part 1.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.3-3"></a>

#### Prespecified criteria for selecting the Part 2 dose

> “The dose for Part 2 will be selected based on safety, efficacy, pharmacokinetics, and health-related patient-reported outcomes in Part 1.”

Source: [Pistilli et al. (2024)](https://olema.com/wp-content/uploads/2024/06/Olema_Final-ASCO2024_OPERA-01-TiP-Poster_6-2-24.pdf)

<a id="topic-3.1.1.3-4"></a>

#### Regulatory alignment on the selected dose

> “today announced it has aligned with the U.S. Food and Drug Administration (FDA) to select 90 mg of palazestrant as the dose for Part 2 of the ongoing registrational Phase 3 OPERA-01 trial in second- and third-line estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-3.1.1.3-5"></a>

#### Stratified randomization

> “Participants (N = 510 overall and 470 in the primary analysis) are randomized to treatment arms using Interactive Response Technology, and randomization is stratified based on 1) the presence of ESR1-mut or absence of detectable ESR1 mutations (ESR1-mut-nd), assessed centrally on circulating tumor DNA (ctDNA) collected during screening period in line with NCCN Guidelines [16]; 2) prior lines of ET for advanced disease (1 vs 2); and 3) presence of visceral disease (yes vs no).”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.3-6"></a>

#### Independent data monitoring committee

> “An independent data monitoring committee (IDMC), comprising medical and statistical representatives not involved in the trial, is monitoring the safety, efficacy, and conduct of the trial.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.3-7"></a>

#### Two-part design as first presented

> “The study consists of two parts: a three-arm dose selection part (part 1), followed by assessment of the selected dose of palazestrant versus standard of care (part 2).”

Source: [Chan et al. (2023c)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OPERA-01-TiP_12-5-23.pdf)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Population

> “Male and female participants aged 18 years or older are eligible for enrollment in the OPERA-01 study if they have a confirmed diagnosis of inoperable locally advanced or metastatic ER+, HER2– breast cancer that is not amenable to curative treatment. Participants must have progressed following treatment with the combination of ET and a CDK4/6i; one additional line of ET is allowed.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.4-2"></a>

#### Key inclusion criteria

> “Evaluable disease (measurable disease or bone-only disease).”
> “Previously received a CDK4/6 inhibitor in combination with an endocrine therapy in the advanced setting. One additional line of ET as a monotherapy is allowed. Duration of the most recent prior ET must be at least 6 months.”
> “Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.”
> “Female participants can be pre-, peri- or postmenopausal.”
> “Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.4-3"></a>

#### Receptor status definitions

> “Laboratory-confirmed ER+, HER2– breast cancer (per ASCO-CAP guidelines)”
> “0 or 1+ by IHC for HER2 membrane protein”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.4-4"></a>

#### Key exclusion criteria

> “Symptomatic visceral disease, imminent organ failure, or any other reason that makes the participant ineligible for endocrine monotherapy.”
> “Previously received chemotherapy in the advanced/metastatic setting.”
> “Previously received treatment with elacestrant or an investigational estrogen receptor-directed therapy.”
> “Symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.4-5"></a>

#### Prior antibody-drug conjugates and washout periods

> “Prior chemotherapy (including ADC) in the advanced/metastatic setting”
> “Fulvestrant, <28 days prior”
> “ET, CDK4/6i, everolimus, tacrolimus, alpelisib, or PARP inhibitors, <14 days prior”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Palazestrant and comparator regimens

> “In Part 2, participants receive once-daily palazestrant (90 mg QD) or SOC ET as described in Part 1. Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.5-2"></a>

#### Comparator doses and schedules

> “Fulvestrant 500 mg IM on day 1 of each 28-day cycle, with an additional dose on day 15 of cycle 1 (recommended for patients who had not previously received fulvestrant), anastrozole 1 mg (oral once daily), letrozole 2.5 mg (oral once daily), and exemestane 25 mg (oral once daily). GnRH agonist requested for premenopausal women and for men.”

Source: [Pistilli et al. (2025)](https://ir.olema.com/static-files/61ec4071-51a5-4a03-aadb-1d296ccd53cb)

<a id="topic-3.1.1.5-3"></a>

#### Treatment cycles and duration

> “All treatments are administered in 28-day cycles and continue until confirmed radiographic disease progression, intolerable toxicity, continuous dose-interruption >28 days, investigator or participant decision, or initiation of a non-protocol anti-cancer therapy.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.5-4"></a>

#### Tablet formulation

> “In OPERA-01 pivotal Phase 3 trial, patients are receiving tablet formulation instead of the capsules utilized in current dataset”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-3.1.1.5-5"></a>

#### Rationale for the endocrine monotherapy control arm

> “The SOC ET in the control arm aligns with the NCCN and ASCO guidelines recommending ET monotherapy as a treatment option to delay chemotherapy, supported by evidence demonstrating sustained endocrine sensitivity and responsiveness of ER+, HER2− breast cancer to fulvestrant, tamoxifen, or non-steroidal AIs ET, even after prior ET failures [16–18,45–51]. As a global study, the SOC control arm has been planned to account for regional variations in standard practices.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Progression-free Survival by Blinded Independent Central Review as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Dual primary endpoint

> “The dual primary endpoint of the overall study is blinded independent committee review (BICR)-assessed PFS, defined as the time from randomization to the date of the first documented progression or death due to any cause, in participants with ESR1-mut and ESR1-mut-nd tumors, to be assessed separately.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.6.1-2"></a>

##### Registered primary outcome measures

> “Dose-Selection Part: Incidence of adverse events”
> “Dose-Selection Part: Incidence of dose reduction”
> “Dose-Selection Part: Incidence of drug discontinuation”
> “To compare PFS, based on a Blinded Independent Review Committee (BIRC) assessment, between arms of OP-1250 and standard-of-care treatment. This will be assessed separately in populations of ESR1-mutation detected and ESR1-mutation not detected participants.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.6.1-3"></a>

##### Rationale for separate analyses by ESR1 mutation status

> “However, recent reports indicate that the clinical benefit in ER+, HER2– ABC may be limited to patients with ESR1-mutated (ESR1-mut) tumors, rather than the entire patient population: trials investigating the efficacy of the PROteolysis Targeting Chimera ER degrader (PROTAC), vepdegestrant, and the SERD, imlunestrant, showed progression-free survival (PFS) benefits specific to patients harboring ESR1 mutations [28,29].”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.6.1-4"></a>

##### Regulatory rationale for progression-free survival

> “PFS can reflect tumor growth and be assessed before the determination of a survival benefit. Its determination is not confounded by subsequent therapy.”
> “When the primary study endpoint is based on tumor measurements (e.g., PFS or ORR), tumor assessments generally should be verified by central reviewers blinded to study treatments (see Appendix) to ascertain lack of assessment bias.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-5"></a>

##### Secondary endpoints

> “Key secondary endpoints of overall survival (OS), defined as the time from randomization to the date of death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another subsequent anti-cancer therapy, will be assessed separately in participants with ESR1-mut and ESR1-mut-nd tumors.”
> “BICR-assessed PFS in the ITT population”
> “PROs (assessed using EQ-5D-5 L and EORTC QLQ-C30)”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.6.1-6"></a>

##### Tumor and safety assessments

> “Adverse event (AE) severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.”
> “Tumor response and disease progression are assessed locally and centrally using body imaging by computed tomography (preferred) or magnetic resonance imaging. Baseline tumor imaging is performed during screening, within 28 days of randomization, and radiographic assessments are conducted periodically.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment

> “Approximately 510 participants are expected to be enrolled, including 470 for the primary analysis.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.7.1-2"></a>

##### Planned enrollment: registry record

| Enrollment type | Participants |
| --- | --- |
| Estimated | “510” |

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.7.1-3"></a>

##### Planned enrollment by part

> “In the dose-selection part of the trial, approximately 120 participants will be randomized to one of the two doses of palazestrant or to the standard-of-care endocrine therapy. Thereafter, approximately 390 participants will be randomized to palazestrant at the selected dose or to the standard-of-care endocrine therapy.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants randomized in Part 1 and planned for the primary comparison

> “The study included the dose selection part where approximately 120 patients were randomized between 90 mg QD palazestrant, 120 mg QD palazestrant, or SOC ET.”
> “Out of 510 patients to be enrolled in total, 470 patients will be randomized between 90 mg QD palazestrant or SOC ET.”

Source: [Pistilli et al. (2025)](https://ir.olema.com/static-files/61ec4071-51a5-4a03-aadb-1d296ccd53cb)

<a id="topic-3.1.1.7.1-5"></a>

##### Planned participants per arm

| Part and arm | Planned participants |
| --- | --- |
| Total | “n = 510” |
| Part 1, each arm (palazestrant 90 mg, palazestrant 120 mg, standard-of-care endocrine therapy) | “n = 40” |
| Part 2, each arm (palazestrant 90 mg, standard-of-care endocrine therapy) | “n = 195 (total 235)” |

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-3.1.1.7.1-6"></a>

##### Enrollment completion

> “Completed enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with second or third-line estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC).”

Source: [Olema Oncology second quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2026-financial-and)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Primary and key secondary analyses

> “Blinded independent committee review (BICR)-assessed PFS, locally assessed PFS, and overall survival (OS) will be analyzed separately in participants with ESR1-mut tumors and participants with ESR1-mut-nd tumors by Kaplan–Meier (KM) methods; median and 95% confidence intervals (CIs) will be reported. Significant differences between treatment groups will be analyzed using the stratified log-rank test, stratified by a number of prior lines of ET and presence or absence of visceral metastases. Cox regression models will be used to estimate hazard ratios and 95% CIs.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.7.2-2"></a>

##### Response endpoints

> “Other secondary endpoints – overall response rate (ORR), CBR, and duration of response (DoR) – will be analyzed using both BICR- and investigator-assessed response evaluations.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.7.2-3"></a>

##### Part 1 dose-selection analysis

> “In Part 1 of the study, the selected dose was based on analyses of safety, preliminary efficacy, PK/pharmacodynamic (PD) parameters, and other relevant clinical and laboratory data, and there was no formal statistical comparison.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

No efficacy or safety results from OPERA-01 have been reported; enrollment is complete, and top-line results are anticipated in the first quarter of 2027. The trial is open label, with PFS assessed by blinded independent central review as the dual primary endpoint. The 90 mg Part 2 dose was chosen from Part 1 data with no formal statistical comparison. The control arm is endocrine monotherapy (fulvestrant or an aromatase inhibitor), and fulvestrant was recommended to participants who had not previously received it. Eligibility excludes participants with prior chemotherapy in the advanced or metastatic setting, prior elacestrant, or symptomatic visceral disease, permits at most one additional line of endocrine therapy after the endocrine therapy and CDK4/6 inhibitor combination, and requires the most recent endocrine therapy to have lasted at least 6 months. Participants receive a tablet formulation, whereas the earlier monotherapy data were obtained with capsules. The trial design publication was funded by Olema Oncology, which was involved in the study design.

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm); [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/); [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738); [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-3.1.1.9-2"></a>

#### Open-label design

> “A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.9-3"></a>

#### Fulvestrant recommended only for participants without prior fulvestrant

> “Fulvestrant was recommended to patients who have not previously received fulvestrant.”
> “The inclusion of AI monotherapy ensures consistency with guideline-supported treatment options across diverse clinical settings [16–18,49].”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.9-4"></a>

#### Sponsor role

> “This manuscript was funded by Olema Oncology. The funder was involved in the study design and collaborated with the authors on the preparation of this manuscript.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
